You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Dow
Moodys
Mallinckrodt
Boehringer Ingelheim

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,247,960

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,247,960
Title:Recovery and processing of human embryos formed in vivo
Abstract: Among other things, uterine lavage is performed to withdraw at least 50% of in vivo fertilized preimplantation embryos produced after superovulation of a woman and artificial insemination using sperm of her sexual partner. After genetic diagnosis or sex determination or gene therapy, or any combination of any two or more of them, of the recovered embryos and selection of at least one of the embryos to be implanted, the selected embryos are returned to the woman for implantation in her uterus.
Inventor(s): Carson; Sandra Ann (Providence, RI), Buster; John E. (Providence, RI)
Assignee: Previvo Genetics, LLC (Piedmont, CA)
Application Number:14/250,240
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,247,960
Patent Claims:1. A process for recovering one or more blastocysts from a uterus of a human, comprising: causing superovulation in the human in a way to form multiple corpora lutea that undergo apoptosis and cannot support development of a viable implanted pregnancy; causing fertilization in vivo of multiple oocytes produced by the superovulation; permitting the fertilized oocytes to mature to form multiple mature preimplantation embryos that present to the uterus as blastocysts; placing a device trans-vaginally into a cervical canal of the human; automatically delivering fluid through the device to the uterus and automatically applying a vacuum to the uterus to aspirate fluid and entrained one or more blastocysts from the uterus without introducing air into the uterus; and causing desynchronization of the endometrium to reduce the chance that any embryos remaining in the uterus will form a viable pregnancy, wherein desynchronization comprises administering GnRH antagonist on the day on which the one or more blastocysts are recovered to induce further corpus luteum apoptosis, suppress luteal phase progesterone, and further decrease risk of a retained pregnancy.

2. The process of claim 1, wherein automatically delivering fluid through the device to the uterus and automatically applying a vacuum to the uterus includes infusing fluid in periodic pulses and applying a vacuum intermittently.

3. The process of claim 1, wherein the device includes an outer guide member and an inner catheter located within the outer guide member, the outer guide member including a seal for isolating the uterus from an external environment; the process including advancing the inner catheter relative to the outer guide member positioning a distal region of the inner catheter within the uterus.

4. The process of claim 3, wherein placing the device comprises locating the seal in the cervical canal.

5. The process of claim 4, wherein locating the seal comprises locating the seal between the internal cervical os and the external cervical os such that the seal does not extend into the vagina or the uterus.

6. The process of claim 1, further comprising storing recovered one or more blastocysts in a container.

7. The process of claim 1, further comprising diagnosing at least one of the one or more blastocysts.

8. The process of claim 7, further comprising treating at least one of the one or more blastocysts.

9. The process of claim 1, further comprising selecting at least one of the one or more blastocysts for implantation.

10. The process of claim 1, further comprising returning at least one of the one or more blastocyst to the uterus.

11. The process of claim 1, further comprising receiving electronically at a clinic information from a host, the information derived from containers that uniquely identify the one or more blastocysts and associates the one or more blastocysts with the human, the information including data that tracks transportation and processing of the one or more blastocysts.

12. The process of claim 1, further comprising: storing recovered one or more blastocysts in a container; diagnosing at least one of the one or more blastocysts; treating at least one of the one or more blastocysts; selecting at least one of the one or more blastocysts for implantation; returning the at least one selected from the one or more blastocyst to the uterus; and receiving electronically at a clinic information from a host, the information derived from the container that uniquely identifies the one or more blastocysts and associates the one or more blastocysts with the human, the information including data that tracks transportation and processing of the one or more blastocysts.

13. The process of claim 12, further comprising transporting the container in an anti-shock insulated transport block.

14. The process of claim 12, wherein the recovered one or more blastocysts are stored in a physiologic transport media.

15. The process claim 1, comprising delivery of FSH to the human's body.

16. The process of claim 15, in which the FSH is delivered by self-injection.

17. The process of claim 15, in which the dosage of FSH is appropriate for induction of superovulation, in vivo fertilization, and embryonic maturation.

18. The process of claim 15, in which the FSH is self-injected using 5 to 15 daily injections at ranges of 37.5 to 600 mIU per day.

19. The process of claim 15, in which the FSH comprises at least one of injectable menotropins containing both FSH and LH, purified FSH given as urofollitropins, recombinant pure FSH, or single doses of long acting pure FSH (recombinant depot FSH).

20. The process of claim 1, comprising administering GnRH antagonists to quiet the ovaries while causing superovulation.

21. The process of claim 20, in which the GnRH antagonists administered while causing superovulation comprise receptor blocker peptides.

22. The process of claim 21, comprising administering a single dose of GnRH agonist subcutaneously or snuffed to trigger the superovulation.

23. The process of claim 20, in which the GnRH antagonists administered while causing superovulation comprise at least one of Ganirelix, Abarelix, Cetrorelix, or Degarelix.

24. The process of claim 20, in which the GnRH antagonists administered while causing superovulation comprise doses ranging from 0.25 to 3.0 mg.

25. The process of claim 1, in which causing superovulation comprises administering GnRH.

26. The process of claim 25, in which the GnRH comprises at least one of Leuprorelin, Leuprolide acetate, nafarelin, or naferilin acetate snuff.

27. The process of claim 1, comprising administering LH or hCG without GnRH agonist.

28. The process of claim 1, comprising administering LH or hCG in combination with GnRH agonist.

29. The process of claim 1, in which impaired corpus luteum estradiol and progesterone production is supplemented to maintain embryonic viability and maturation.

30. The process of claim 29, comprising administrating progesterone and estradiol until recovery of the one or more blastocysts.

31. The process of claim 30, in which the progesterone comprises at least one of vaginal progesterone, or oral progesterone and the estradiol comprises at least one of oral or transdermal estradiol.

32. The process of claim 31, in which the progesterone comprises vaginal progesterone administered at 1 application per day or in 200 mg doses at 3 applications per day, or oral progesterone administered in 200 mg doses at 3 oral capsules per day, and the estradiol comprises transdermal estradiol patches 400 .mu.g per day or oral estradiol 4.0 mg per day.

33. The process of claim 30, in which blastocyst implantation is prevented by discontinuing administration of estradiol and progesterone starting on the day of blastocysts recovery on the day of lavage.

34. The process of claim 1, in which desynchronization comprises administering progesterone receptor antagonist.

35. The process of claim 34, in which the administering comprises a single dose of progesterone receptor antagonist comprising Mifepristone at a dosage amount of 600 mg injected into the uterus with a second dose comprising Mifepristone at a dosage of 600 mg given by mouth one day prior to expected menses.

36. The process of claim 1, in which administering the GnRH antagonist comprises administering a single 3.0 mg dose of the GnRH antagonist.

37. The process of claim 1, wherein the vacuum is applied in between each pulsation of the fluid.

38. The process of claim 1, wherein the process avoids delivering fluid and the entrained one or more blastocysts into the Fallopian tubes of the human.

39. A process for recovering one or more blastocysts from a uterus of a human, comprising: placing a device trans-vaginally into a cervical canal of the human; cyclically delivering fluid through the device to the uterus and applying a vacuum to the uterus to aspirate fluid and entrained one or more blastocysts from the uterus without introducing air into the uterus; and causing desynchronization of the endometrium to reduce the chance that any embryos remaining in the uterus will form a viable pregnancy, wherein said causing desynchronization comprises administering GnRH antagonist on the day on which the one or more blastocysts are recovered to induce further corpus luteum apoptosis, suppress luteal phase progesterone, and further decrease risk of a retained pregnancy.

40. The process of claim 39, in which the GnRH antagonists comprise doses ranging from 0.25 to 3.0 mg.

41. The process of claim 39, in which administering the GnRH antagonist comprises administering a single 3.0 mg dose of the GnRH antagonist.

42. The process of claim 39, wherein the vacuum is applied in between each pulsation of the fluid.

43. The process of claim 39, wherein the process avoids delivering fluid and the entrained one or more blastocysts into the Fallopian tubes of the human.

44. The process of claim 39, further comprising storing recovered one or more blastocysts in a container.

45. The process of claim 39, further comprising diagnosing at least one of the one or more blastocysts.

46. The process of claim 45, further comprising treating at least one of the one or more blastocysts.

47. The process of claim 39, further comprising selecting at least one of the one or more blastocysts for implantation.

48. The process of claim 39, further comprising returning at least one of the one or more blastocyst to the uterus.

49. The process of claim 39, further comprising receiving electronically at a clinic information from a host, the information derived from containers that uniquely identify the one or more blastocysts and associates the one or more blastocysts with the human, the information including data that tracks transportation and processing of the one or more blastocysts.

50. A process for recovering one or more blastocysts from a uterus of a human, comprising: placing a device trans-vaginally into a cervical canal of the human; cyclically delivering fluid through the device to the uterus and applying a vacuum to the uterus to aspirate fluid and entrained one or more blastocysts from the uterus without introducing air into the uterus; causing superovulation in the human in a way to form multiple corpora lutea that undergo apoptosis and cannot support development of a viable implanted pregnancy; causing fertilization in vivo of multiple oocytes produced by the superovulation; permitting the fertilized oocytes to mature to form multiple mature preimplantation embryos that present to the uterus as blastocysts; and causing desynchronization of the endometrium to reduce the chance that any embryos remaining in the uterus will form a viable pregnancy, wherein said causing desynchronization comprises administering GnRH antagonist on the day on which the one or more blastocysts are recovered to induce further corpus luteum apoptosis, suppress luteal phase progesterone, and further decrease risk of a retained pregnancy.

51. A process for recovering one or more blastocysts from a uterus of a human, comprising: causing superovulation in the human in a way to form multiple corpora lutea that undergo apoptosis and cannot support development of a viable implanted pregnancy; causing fertilization in vivo of multiple oocytes produced by the superovulation; permitting the fertilized oocytes to mature to form multiple mature preimplantation embryos that present to the uterus as blastocysts; placing a device trans-vaginally into a cervical canal of the human; automatically delivering fluid through the device to the uterus and automatically applying a vacuum to the uterus to aspirate fluid and entrained one or more blastocysts from the uterus without introducing air into the uterus; and causing desynchronization of the endometrium to reduce the chance that any embryos remaining in the uterus will form a viable pregnancy, wherein impaired corpus luteum estradiol and progesterone production is supplemented to maintain embryonic viability and maturation.

52. The process of claim 51, comprising administrating progesterone and estradiol until recovery of the one or more blastocysts.

53. The process of claim 52, in which the progesterone comprises at least one of vaginal progesterone, or oral progesterone and the estradiol comprises at least one of oral or transdermal estradiol.

54. The process of claim 53, in which the progesterone comprises vaginal progesterone administered at 1 application per day or in 200 mg doses at 3 applications per day, or oral progesterone administered in 200 mg doses at 3 oral capsules per day, and the estradiol comprises transdermal estradiol patches 400 .mu.g per day or oral estradiol 4.0 mg per day.

55. The process of claim 52, in which blastocyst implantation is prevented by discontinuing administration of estradiol and progesterone starting on the day of blastocysts recovery on the day of lavage.

Details for Patent 9,247,960

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Ferring MENOPUR menotropins (fsh;lh) INJECTABLE;SUBCUTANEOUS 021663 001 2006-03-20   Start Trial Previvo Genetics, LLC (Piedmont, CA) 2031-12-22 RX search
Ferring Pharmaceuticals Inc. MENOPUR menotropins KIT 021663 1 2004-10-29   Start Trial Previvo Genetics, LLC (Piedmont, CA) 2031-12-22 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Harvard Business School
Medtronic
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.